Last update 08 May 2025
Lilly Asia Shanghai Representative Office

Lilly Asia Shanghai Representative Office

Private Company|1993|Shanghai Shi, China

Overview

Tags

Nervous System Diseases
Endocrinology and Metabolic Disease
Other Diseases
Small molecule drug
Synthetic peptide
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases6
Endocrinology and Metabolic Disease6
Immune System Diseases4
Neoplasms4
Infectious Diseases2
Hemic and Lymphatic Diseases1
Top 5 Drug TypeCount
Small molecule drug5
Hormone1
Biosimilar1
Synthetic peptide1
Monoclonal antibody1
Top 5 TargetCount
JAK1 x JAK21
GIPR x GLP-1R1
INSR(Insulin receptor)1
ALK5(Transforming growth factor beta receptor 1)1
CDK4 x CDK61

Related

15
Drugs associated with Lilly Asia Shanghai Representative Office
Mirikizumab
Target
IL-23p19
Mechanism
IL-23p19 inhibitors [+1]
Active Org.
Eli Lilly & Co.Eli Lilly & Co. [+5]
Originator Org.
Eli Lilly & Co.Eli Lilly & Co.
Active Indication
Ulcerative colitis, active moderate [+7]
Inactive Indication
Plaque psoriasis [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date27 Mar 2023
Tirzepatide
Target
GIPR x GLP-1R
Mechanism
GIPR agonists [+1]
Active Org.
Eli Lilly Canada, Inc. [+9]
Originator Org.
Lexaria Bioscience Corp.Lexaria Bioscience Corp. [+1]
Active Indication
Sleep Apnea, Obstructive [+16]
Inactive Indication
Hypoglycemia [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date13 May 2022
Selpercatinib
Target
RET
Mechanism
RET inhibitors
Active Org.
Eli Lilly & Co.Eli Lilly & Co. [+6]
Originator Org.
Loxo Oncology, Inc.Loxo Oncology, Inc.
Active Indication
RET fusion-positive Solid Tumors [+20]
Inactive Indication
Liver Injury
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date08 May 2020
46
Clinical Trials associated with Lilly Asia Shanghai Representative Office
CTR20233072
/ RecruitingNot Applicable
一项评价塞普替尼胶囊（Selpercatinib Capsules）治疗晚期或转移性RET基因融合阳性甲状腺癌（成人和儿童）患者有效性和安全性的（前瞻性、非干预性、）上市后观察性研究
[Translation] A prospective, non-interventional, post-marketing observational study to evaluate the efficacy and safety of selpercatinib capsules in the treatment of advanced or metastatic RET gene fusion-positive thyroid cancer (adults and children)
CTR20202116
/ CompletedPhase 3
一项在接受滴定基础胰岛素治疗的中国2 型糖尿病患者中比较联合使用度拉糖肽1.5 mg 与联合使用安慰剂对血糖控制影响的随机、双盲试验
[Translation] A randomized, double-blind trial comparing the effects of dulaglutide 1.5 mg versus placebo on glycemic control in Chinese patients with type 2 diabetes receiving titrated basal insulin
CTR20200092
/ CompletedPhase 3
在中重度活动性克罗恩病患者中评价Mirikizumab的有效性和安全性3期多中心随机双盲安慰剂和活性对照治疗研究
[Translation] A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
100 Clinical Results associated with Lilly Asia Shanghai Representative Office
Login to view more data
0 Patents (Medical) associated with Lilly Asia Shanghai Representative Office
Login to view more data
100 Deals associated with Lilly Asia Shanghai Representative Office
Login to view more data
100 Translational Medicine associated with Lilly Asia Shanghai Representative Office
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
7
Phase 3 Clinical
Other
7
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free